UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
We investigated whether UGT1A1 polymorphisms are associated with the prognosis of ovarian cancer patients treated with irinotecan. UGT1A1 genotypes were analyzed in 11 stage I ovarian clear cell carcinoma patients who received irinotecan as first-line therapy. Progression-free survival, overall survival and adverse events were also assessed for each genotype. Three patients harbored UGT1A1*1/*6 while another three harbored UGT1A1*1/*28. Two patients with a wild-type genotype experienced recurrence and one died, whereas no recurrence or death was observed in patients with heterozygous genotypes. Adverse events tended to be more severe in patients with UGT1A1*6 and *28, although progression-free survival and overall survival rates tended to be better than in wild-type; the differences were not significant. We conclude that UGT1A1 polymorphisms have the potential to be a prognostic marker of irinotecan treatment.
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.|Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Tomoko
T
Yoshihama
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Akira
A
Hirasawa
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Hiroyuki
H
Nomura
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Tomoko
T
Akahane
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Yoshiko
Y
Nanki
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Wataru
W
Yamagami
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Fumio
F
Kataoka
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Eiichiro
E
Tominaga
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Nobuyuki
N
Susumu
Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Taisei
T
Mushiroda
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Daisuke
D
Aoki
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D020022:Genetic Predisposition to Disease; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D000099148:UGT1A1 Enzyme
D000972:Antineoplastic Agents, Phytogenic; D002166:Camptothecin; D014453:Glucuronosyltransferase; D000077146:Irinotecan; D000099148:UGT1A1 Enzyme
UGT1A1; pharmacogenomics; irinotecan; ovarian cancer